Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16

被引：14

作者：

Egan, N ^{[1
]}

O'Reilly, J ^{[1
]}

Chipper, L ^{[1
]}

Higgins, M ^{[1
]}

Herrmann, R ^{[1
]}

Cannell, P ^{[1
]}

机构：

[1] Royal Perth Hosp, Dept Haematol, Perth, WA 6001, Australia

来源：

CANCER GENETICS AND CYTOGENETICS | 2004年 / 154卷 / 01期

关键词：

D O I：

10.1016/j.cancergencyto.2004.01.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myelomonocytic leukemia with bone marrow eosinophilia (AML M4Eo) is a subtype of AML with distinct morphological features. Inversion (16)(p13.1q22), t(16;16)(p13.1;q22), and del(16)(q22) are nonrandom abnormalities associated with AML M4Eo and a favorable prognosis, compared with the standard risk group for AML. Deletions of the proximal region of the MYH11 gene located at 16p13.1 have been detected in about 20% of patients with inv(16), with an undetermined effect on patient survival. We present the case of a patient with AML M4Eo and inversion 16 with a distal deletion of the CBFB gene at 16q22 detected with fluorescence in situ hybridization. To our knowledge, only one previous report of a similar deletion has appeared in the literature. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：60 / 62

页数：3

共 13 条

[1] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[2]

CLAXTON DF, 1994, BLOOD, V83, P1750

[3] Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene:: expression profiling, resistance to interferon therapy, and poor prognosis [J].

Cohen, N ;

Rozenfeld-Granot, G ;

Hardan, I ;

Brok-Simoni, F ;

Amariglio, N ;

Rechavi, G ;

Trakhtenbrot, L .

CANCER GENETICS AND CYTOGENETICS, 2001, 128 (02) :114-119

[4] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[5] Deletion of the 5′-ABL region:: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients [J].

Herens, C ;

Tassin, F ;

Lemaire, V ;

Beguin, Y ;

Collard, E ;

Lampertz, S ;

Croisiau, C ;

Lecomte, M ;

De Prijk, B ;

Longrée, L ;

Koulischer, L .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (01) :214-216

[6] Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [J].

Huntly, BJP ;

Reid, AG ;

Bench, AJ ;

Campbell, LJ ;

Telford, N ;

Shepherd, P ;

Szer, J ;

Prince, HM ;

Turner, P ;

Grace, C ;

Nacheva, EP ;

Green, AR .

BLOOD, 2001, 98 (06) :1732-1738

[7] Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis [J].

Kolomietz, E ;

Al-Maghrabi, J ;

Brennan, S ;

Karaskova, J ;

Minkin, S ;

Lipton, J ;

Squire, JA .

BLOOD, 2001, 97 (11) :3581-3588

[8]

LARSON RA, 1986, BLOOD, V68, P1242

[9] MOLECULAR CHARACTERIZATION OF 16P DELETIONS ASSOCIATED WITH INVERSION-16 DEFINES THE CRITICAL FUSION FOR LEUKEMOGENESIS [J].

MARLTON, P ;

CLAXTON, DF ;

LIU, P ;

ESTEY, EH ;

BERAN, M ;

LEBEAU, M ;

TESTA, JR ;

COLLINS, FS ;

ROWLEY, JD ;

SICILIANO, MJ .

BLOOD, 1995, 85 (03) :772-779

[10]

MARLTON P, 1995, LEUKEMIA, V9, P965

← 1 2 →